## Nikolaos Tsamandouras

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10455562/publications.pdf

Version: 2024-02-01

933447 1281871 11 943 10 11 citations g-index h-index papers 11 11 11 1552 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure–response analysis. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 605-616.	1.8	2
2	Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies. Scientific Reports, 2018, 8, 4530.	3.3	341
3	Physiologically Relevant, Humanized Intestinal Systems to Study Metabolism and Transport of Small Molecule Therapeutics. Drug Metabolism and Disposition, 2018, 46, 1581-1587.	3.3	13
4	Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population. Pharmacogenetics and Genomics, 2017, 27, 27-38.	1.5	16
5	Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies. AAPS Journal, 2017, 19, 1499-1512.	4.4	177
6	Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction. Journal of Allergy and Clinical Immunology, 2017, 139, 771-779.e10.	2.9	72
7	Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data. AAPS Journal, 2016, 18, 196-209.	4.4	19
8	Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. Pharmaceutical Research, 2015, 32, 1864-1883.	3.5	52
9	Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 349-373.	1.8	13
10	Combining the †bottom up†and †top down†approaches in pharmacokinetic modelling: fitting <scp>PBPK &lt; scp&gt; models to observed clinical data. British Journal of Clinical Pharmacology, 2015, 79, 48-55.</scp>	2.4	198
11	Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk. Pharmaceutical Research, 2014, 31, 2367-2382.	3.5	40